Erianin mitigates diabetic cardiomyopathy via adenosine monophosphate-activated protein kinase-nuclear factor erythroid 2-related factor 2-heme oxygenase-1 pathway activation

Figure 9 Inhibition of nuclear factor erythroid 2-related factor 2 reverses the effect of erianin on type 2 diabetes mellitus mice. A: Hematoxylin-eosin-stained myocardial section; B: Markers of myocardial damage; C: Serum proinflammatory factors; D: mRNA levels of proinflammatory factors; E: Oxidative stress. Bar charts represent the mean ± SEM, n = 8. ^aP < 0.05 vs control group; ^bP < 0.01 vs control group; ^cP < 0.001 vs control group; ^dP < 0.05 vs model group; ^eP < 0.01 vs model group; ^fP < 0.001 vs model group; CK: Creatine kinase; CK-MB: Creatine kinase-isoenzymes; cThI: Cardiac troponin I; TNF-α: Tumor necrosis factor-α; IL: Interleukin; MDA: Malondialdehyde; SOD: Superoxide dismutase; CAT: Catalase.